Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.70 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.70 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.70 |
| ▸ | SRC | P12931 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | HKDC1 | Q2TB90 | 4/20 | 0.69 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17969781 | 0.94 | ALDH1A1 (0.78) | PPARGFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL3576647 | 0.88 | PPARG (0.76) | PPARGFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL8359086 | 0.87 | PPARG (0.63) | PPARGFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL3570952 | 0.86 | PPARG (0.74) | PPARGFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL9904567 | 0.85 | MAPT (0.78) | PPARGFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL3572575 | 0.84 | PPARG (1.00) | PPARGFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL5138100 | 0.84 | PPARG (0.56) | PPARGFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL3572958 | 0.83 | PPARG (0.69) | PPARGFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL13561203 | 0.83 | HSP90AA1 (0.74) | PPARGFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL143675 | 0.83 | FGFR1 (1.00) | PPARGFGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448260-B2 | 3-(2-CARBOXYMETHOXY-4-METHOXYPHENYL)-1-(3,4-METHYLENEDIOXY -PHENYL)-5-(PROP-1-YLOXY)-INDANE-2-CARBOXYLIC ACID AS AN ESPECIALLY PREFERRED COMPOUND; HYPOTENSIVE AGENTS; CARDIOVASCULAR, UROGENITAL AND RESPIRATORY DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-09-10 | — | — | US | disclosed |
| US-20020002177-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | disclosed |
| EP-0612244-B1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6274737-B1 | CARDIOVASCULAR DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-08-14 | — | — | US | disclosed |
| US-6271399-B1 | METHYL 3-(3,4-METHYLENEDIOXYPHENYL)-6-(PROP-1-YLOXY)-INDANE-2-CARBOXYLATE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION | 2001-08-07 | — | — | US | disclosed |
| US-6087389-A | TREATING CARDIOVASCULAR AND RENAL DISEASES INCLUDING HYPERTENSION, ACUTE AND CHRONIC RENAL FAILURE, CYCLOSPORINE INDUCED NEPHROTOXICITY, STROKE, CEREBROVASCULAR VASOSPASM, MYOCARDIAL ISCHEMIA, ANGINA, HEART FAILURE, ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
| US-5817693-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 1998-10-06 | — | — | US | disclosed |
| US-5719183-A | HYPOTENSIVE AGENTS; KIDNEY DISEASES; ANTIISCHEMIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5719182-A | TREATING HYPERTENSION, RENAL FAILURE, CEREBROVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5716984-A | INDANE AND INDENE DERIVATIVES; TREATMENT OF CARDIOVASCULAR DISORDERS, KIDNEY DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0612244-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM CORP (US) | 1995-05-17 | — | — | EP | disclosed |
| EP-0612244-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-08-31 | — | — | EP | disclosed |
| WO-1993008799-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002177-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | PPARG 2419/4885FGFR1 1048/4885FGFR2 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.